8-K: Immunocore Reports Strong Q3 2024 Results with KIMMTRAK Sales Growth and Pipeline Advancements

Immunocore announced a strong third quarter with significant revenue growth for KIMMTRAK and progress in its clinical pipeline.

Summary

• Immunocore reported a successful third quarter of 2024, with KIMMTRAK net revenues reaching $80.2 million, a 28% increase compared to the same period in 2023.
• The company's total revenue for the quarter was $80.2 million, and net income was $8.7 million, a significant increase from $0.9 million in the same quarter of the previous year.
• Earnings per share (EPS) for the quarter were $0.17, compared to $0.02 in Q3 2023.
• KIMMTRAK sales for the first nine months of 2024 totaled $225.9 million, a 32% increase year-over-year.
• The company is advancing multiple clinical trials, including Phase 3 trials for cutaneous melanoma (PRISM-MEL-301 and TEBE-AM) and adjuvant uveal melanoma (ATOM).
• Immunocore has $901.3 million in cash, cash equivalents, and marketable securities as of September 30, 2024.
• The company plans to repay its $50 million loan and approximately $40 million in sales-related rebate accruals by the end of 2024.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong financial results, significant clinical progress, and a robust cash position. The delay in the NSCLC data release is a minor concern, but overall the sentiment is very positive.

Positives

• KIMMTRAK continues to show strong sales growth, driven by increased demand in the US and Germany and expanded patient reach.
• The company is making significant progress in its clinical pipeline, with multiple Phase 3 trials underway.
• Positive clinical data for brenetafusp in ovarian cancer was presented at ESMO 2024.
• The company is expanding its platform into autoimmune diseases with two new bispecific candidates.
• Immunocore has a strong cash position of $901.3 million.
• The company is on track to repay its $50 million loan by the end of 2024.

Negatives

• The initial data release for brenetafusp in metastatic NSCLC has been shifted, with a focus now on earlier-line patients and combinations.
• Research and development expenses increased to $52.8 million in Q3 2024, compared to $43.2 million in Q3 2023.
• The company is searching for a new CFO as the current CFO is leaving at the end of the year.

Risks

• The company faces risks related to the impact of worsening macroeconomic conditions on its business and clinical trials.
• There are risks associated with obtaining and maintaining regulatory approval for its product candidates.
• The company faces competition in the market for its therapies.
• Unexpected safety or efficacy data from clinical trials could impact the company's progress.
• The company may need to obtain additional funding in the future.

Future Outlook

The company expects continued growth for KIMMTRAK and is focused on advancing its clinical pipeline, including the Phase 3 trials for cutaneous and uveal melanoma. They also plan to expand into autoimmune diseases and infectious diseases. The company intends to repay its $50 million loan and approximately $40 million in sales-related rebate accruals by the end of 2024.

Management Comments

• We are proud to report another strong quarter, marking two years of continuous growth for KIMMTRAK and another quarter of positive net income, said Bahija Jallal, Immunocores Chief Executive Officer.
• We are also making significant strides in advancing our broad pipeline with brenetafusp in oncology, the HIV functional cure trial in infectious diseases, and in autoimmune diseases with tissue-targeted programs for type 1 diabetes and dermatologic diseases.
• KIMMTRAKs 28% growth over Q3 last year is driven by higher demand in the United States and Germany and by expanded patient reach with 11 launches this year, said Ralph Torbay, Immunocores Chief Commercial Officer.

Industry Context

This announcement reflects the ongoing growth in the immuno-oncology space, with Immunocore leveraging its ImmTAC technology to develop novel therapies. The company's focus on bispecific antibodies and T-cell redirection aligns with current trends in cancer treatment. The expansion into autoimmune and infectious diseases also positions Immunocore as a diversified player in the biotechnology sector.

Comparison to Industry Standards

• Immunocore's 28% year-over-year growth in KIMMTRAK sales is strong compared to other commercial-stage biotech companies in the oncology space, such as Xencor which reported a 20% increase in revenue for their lead product in their most recent quarter.
• The 58% disease control rate in monotherapy and 69% in combination therapy for brenetafusp in platinum-resistant ovarian cancer is competitive with other experimental therapies in this space, such as Mirvetuximab Soravtansine which has shown similar response rates in clinical trials.
• The company's cash position of $901.3 million is robust compared to other companies of similar size, providing a strong financial foundation for continued research and development.
• The company's focus on novel targets like PIWIL1 for colorectal cancer is a unique approach compared to other companies primarily focused on checkpoint inhibitors.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and clinical progress.
• Employees may be impacted by the CFO transition, but the company is ensuring a smooth transition.
• Patients with uveal melanoma and other cancers may benefit from the company's ongoing clinical trials and potential new therapies.
• Customers (healthcare providers) will continue to have access to KIMMTRAK and potentially new therapies in the future.
• Suppliers and creditors will be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will continue to enroll patients in ongoing Phase 3 trials for cutaneous and uveal melanoma.
• Randomization in the ATOM Phase 3 trial is expected to start in Q4 2024.
• The company will continue signal detection for brenetafusp in metastatic non-small-cell lung cancer cohorts.
• The first patient is expected to be treated in the Phase 1 trial with IMC-P115C in the first half of 2025.
• The company will complete the single ascending dose (SAD) portion of the Phase 1 trial of IMC-I109V for people living with HBV in Q4 2024.
• Data from the Phase 1 trial of IMC-M113V for people living with HIV is expected in the first quarter of 2025.

Key Dates

Keywords

KIMMTRAK, Immunocore, brenetafusp, uveal melanoma, cutaneous melanoma, clinical trials, ImmTAC, oncology, immunotherapy, PRAME, HIV, autoimmune diseases